Pia - About the company
Pia is an unfunded company based in Shinagawa (Japan), founded in 2011. It operates as a Developer of stem cell-derived exosomes for dermatological conditions. Pia has not raised any funding yet. The company has 13 active competitors, including 4 funded and 2 that have exited. Its top competitors include companies like PranaX, ELEVAI Labs and ExocoBio.
Company Details
Developer of stem cell-derived exosomes for dermatological conditions. It offers human adipose stromal cell exosomes know as "VECEL", a cosmetic product with a high exosome content, and "Exollēn", a professional cosmetics brand for aging conditions.
- Website
- www.pia-corp.co.jp/
- Phone Number
- +81 **********
Key Metrics
Sign up to download Pia's company profile
Pia's funding and investors
Pia has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Pia's Competitors and alternates
Top competitors of Pia include PranaX, ELEVAI Labs and ExocoBio. Here is the list of Top 10 competitors of Pia, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  PranaX 2022, Houston (United States), Series A | Provider of regenerative science to treat various health conditions | $27M | - | 56/100 |
2nd |  ELEVAI Labs 2020, California City (United States), Public | Developer of regenerative aesthetic dermatology products | - | - | 47/100 |
3rd | ExocoBio 2017, Seoul (South Korea), Series C | Developer of exosome-based therapeutics for regenerative medicine | $47.3M | 44/100 | |
4th | Developer of stem cell-derived exosomes for dermatological conditions | - | - | 38/100 | |
5th | Aegle Therapeutics 2013, Miami (United States), Series A | Developing extracellular vesicle therapies for debilitating rare diseases and dermatological disorders | $6.5M | 37/100 | |
6th |  Brexogen 2019, Seoul (South Korea), Series A | Developer of exosome therapies for various conditions | $5.38M | 35/100 | |
7th |  Exotropin 2023, New York (United States), Unfunded | Developer of exosome-based health and beauty products | - | - | 32/100 |
8th | NextPhase Therapeutics 2020, Seattle (United States), Unfunded | Developer of topical therapeutics for dermatological diseases | - | - | 30/100 |
9th | Prostemics 2005, Seoul (South Korea), Public | Manufacturer of device and drugs for skin care | - | 25/100 | |
10th |  Design Cell 2016, Cheongju-si (South Korea), Unfunded | Developer of stem cell technologies for the treatment of various diseases | - | - | 24/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Pia's competitors? Click here to see the top ones
Pia's Investments and acquisitions
Pia has made no investments or acquisitions yet.
Reports related to Pia
Here is the latest report on Pia's sector:
News related to Pia
Media has covered Pia for 1 event in last 1 year.
•
feliamo's "Sheer Brown" Color Contact Lenses Awarded "A Evaluation" by LDK the BeautyPR TIMES•Feb 16, 2026•Pia
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Pia
Explore our recently published companies
- Biz Logic - Colombia based, 2010 founded, Unfunded company
- PARMENIDES Project - Unfunded company
- PigeonShip - Provo based, Unfunded company
- MIE CCTV - Bromsgrove based, 2012 founded, Unfunded company
- Decision Group - Taiwan based, 1986 founded, Unfunded company
- OctoClassic - London based, 2019 founded, Unfunded company
